| __timestamp | Geron Corporation | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 16758000 | 17986000 |
| Thursday, January 1, 2015 | 17793000 | 32480000 |
| Friday, January 1, 2016 | 18761000 | 68081000 |
| Sunday, January 1, 2017 | 19287000 | 169906000 |
| Monday, January 1, 2018 | 18707000 | 248932000 |
| Tuesday, January 1, 2019 | 20893000 | 354100000 |
| Wednesday, January 1, 2020 | 25678000 | 433300000 |
| Friday, January 1, 2021 | 29665000 | 583300000 |
| Saturday, January 1, 2022 | 43628000 | 752700000 |
| Sunday, January 1, 2023 | 69135000 | 887600000 |
| Monday, January 1, 2024 | 1007200000 |
Infusing magic into the data realm
In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Neurocrine Biosciences, Inc. and Geron Corporation from 2014 to 2023. Over this period, Neurocrine Biosciences has seen a staggering increase in SG&A expenses, growing from approximately $18 million in 2014 to nearly $888 million in 2023. This represents a growth of nearly 4,800%, reflecting the company's aggressive expansion and investment in its operational infrastructure.
In contrast, Geron Corporation's SG&A expenses have grown more modestly, from around $17 million in 2014 to $69 million in 2023, marking a 310% increase. This difference highlights the distinct strategic approaches of these two companies, with Neurocrine focusing on rapid growth and Geron maintaining a more conservative expenditure strategy. Understanding these trends provides valuable insights into the operational efficiencies and strategic priorities of these biotech firms.
Comparing SG&A Expenses: Eli Lilly and Company vs Neurocrine Biosciences, Inc. Trends and Insights
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Neurocrine Biosciences, Inc.
Breaking Down SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
Comparing Cost of Revenue Efficiency: Neurocrine Biosciences, Inc. vs Geron Corporation
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Cytokinetics, Incorporated and Geron Corporation
Cost Management Insights: SG&A Expenses for ACADIA Pharmaceuticals Inc. and Geron Corporation
Who Optimizes SG&A Costs Better? Geron Corporation or Wave Life Sciences Ltd.